L’administration sous-cutanée de la téicoplanine permet-elle d’atteindre les objectifs thérapeutiques de téicoplaninémie résiduelle ? Évaluation rétrospective multicentrique au cours des infections ostéo-articulaires staphylococciques
Year: 2016
Type: dissertation
Study design: Observational Study
Abstract: Context: Subcutaneous administration of antibiotic therapy is routinely practiced by 95% of infectious disease specialists, despite this practice is usually off label. Teicoplanin may constitute an acceptable alternative in the treatment of staphylococcal bone and joint infection. It could be theoretically used by subcutaneous route, and then allow to reduce the length of hospitalization and avoid long-term venous central catheter. Nevertheless, this administration route has not been well evaluated yet. Our objective was to assess the trough concentration of teicoplanin obtained during subcutaneous administration in staphylococcal bone and joint infection (target trough concentration ≥ 15 mg/L), and to describe its efficacy and tolerance. Methods: All patients receiving teicoplanin by subcutaneous route for a staphylococcal bone and joint infection (excepting diabetic foot infection) between 2002 and 2015 were included in a retrospective multicentric cohort study in three French hospital centers (Chambery, Lyon, and Strasbourg). Results: Forty episodes of bone and joint infections were assessed, including 34 orthopedic device-related infections (85%) and 21 chronic infections (53%). The median age was 75 years (IQR, 62-84). The median glomerular filtration rate (GFR) was 68 ml/min/m2 (IQR, 56-91). Twenty-four isolates were methicillin-resistant (58%), including 13 Staphylococcus aureus and 11 coagulase negative Staphylococci, with a MIC for teicoplanin of 0.5 mg/L (IQR, 0.38-0.81) and 0.75 mg/L (IQR, 0.5-1), respectively. The median duration of treatment by teicoplanin was 46 days (IQR, 29-79), primarily in combination with rifampin (n = 23) or a fluoroquinolone (n = 16). Sixteen patients (40%) received a loading dose by intravenous route before switching to subcutaneous route. A median loading dose of 9.4 mg/kg/12 h (IQR, 6.1-13.1) was used in 35 patients (88%) (16 by IV route, 18 by SC route, 1 by IM route). The maintenance dose was 7.3 mg/kg/injection (IQR, 5.3-12.1). A 3 injections per week scheme of 15 mg/kg/injection (IQR, 10.3-15.9) was conducted in 13 (33%) patients. A trough concentration ≥ 15 mg/L was reached in 34 patients (85%) in a median delay of 4 days (IQR, 3-6). The trough concentrations during the first 20 days were not significantly different between the IV and SC (p = 0.462) routes. Trough concentrations reached by subcutaneous route were significantly higher if the loading dose was ≥ 9 mg/kg/injection (p < 10-3). Fifteen treatment failures were observed (37.5%), including 8 superinfections. Nine adverse effects were reported in 6 patients (15%), mainly haematological (n = 3) and cutaneous (n = 2). Conclusion: In our series, the use of teicoplanin by subcutaneous route allowed to achieve a target trough concentration ≥ 15 mg/L. This target was reached faster if the loading dose was ≥ 9mg/kg/injection. Subcutaneous route consequently allowed facilitating the long-term parenteral antibiotherapy of staphylococcal bone and joint infections. Its clinical efficacy and its tolerance appeared to be acceptable, but have to be validated by future larger prospective trials.
Source: HAL
Author: A. Destrem
Institution: Université Grenoble Alpes
Language: French
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2343127918
